TABLE 2.
Baseline demographics and characteristics. Clinical characteristics of study participants
| Type 2 | Type 3a | Type 3b | Controls | |
|---|---|---|---|---|
| n | 15 | 7 | 9 | 20 |
| Sex (M:F) | 6:9 | 3:4 | 6:3 | 8:12 |
| Age in years (range) | 24.9 (7‐73) | 23.5 (7‐49) | 42.0 (18‐55) | 37.9 (17‐71) |
| Mean disease duration in months (SD; range) | 276 (172; 82‐661) | 265 (202; 69‐581) | 362 (180; 77‐661) | ‐ |
| Ambulatory status | ||||
| Ambulatory, n (%) | ‐ | 3 (43%) | 8 (89%) | 20 (100%) |
| Nonambulatory, n (%) | 15 (100%) | 4 (57%) | 1 (11%) | ‐ |
| Clinical measurements | ||||
| Mean MRC sum score (SD) | 110 (34.4) | 151 (43.7) | 177 (38.8) | 229 (2) |
| Mean MRC score lower extremities (SD) | 11 (4.8) | 15 (6.4) | 17 (6.8) | 30 (−) |
| Mean HFMSE score (SD; range) | 5.9 (10; 0‐36) | 28.4 (22.8; 0‐53) | 40.0 (18.0; 2‐63) | ‐ |
Abbreviations: F, female; HFMSE, Hammersmith Motor Function Scale Expanded; M, male; MRC, Medical Research Council; N, number; SD, standard deviation.